Nafamostat mesylate (NM), a previously discovered serine protease inhibitor used for the treatment of pancreatitis and cancers, was recently identified as a competitive or allosteric FTO inhibitor (IC50 = 13.77 μM) (Fig. 6b). This evidence concerns the gene FTO and cancer.